October 29, 2019 09:52 AM EDT

Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T

Kathy Wong

Editor

→ Regeneron and Sanofi‘s Dupixent — a king in the eczema therapy sector — has cinched its third type 2 inflammatory disease approval in the EU …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T

Kathy Wong

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Investors pump $130M into protein degrader startup GlycoEra

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Dupix­ent cleared for chron­ic rhi­nos­i­nusi­tis in EU; FDA grants RMAT sta­tus to CARs­gen's CAR-T

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T